76 related articles for article (PubMed ID: 38549690)
1. A systematic evidence map of chronic inflammation and immunosuppression related to per- and polyfluoroalkyl substance (PFAS) exposure.
Zhang L; Louie A; Rigutto G; Guo H; Zhao Y; Ahn S; Dahlberg S; Sholinbeck M; Smith MT
Environ Res; 2023 Mar; 220():115188. PubMed ID: 36592815
[TBL] [Abstract][Full Text] [Related]
2. Per- and polyfluoroalkyl substances (PFASs) in Chinese surface water: Temporal trends and geographical distribution.
Wang J; Shen C; Zhang J; Lou G; Shan S; Zhao Y; Man YB; Li Y
Sci Total Environ; 2024 Mar; 915():170127. PubMed ID: 38242487
[TBL] [Abstract][Full Text] [Related]
3. Determination of
Janssen AWF; Jansen Holleboom W; Rijkers D; Louisse J; Hoekstra SA; Schild S; Vrolijk MF; Hoogenboom RLAP; Beekmann K
Front Toxicol; 2024; 6():1347965. PubMed ID: 38549690
[TBL] [Abstract][Full Text] [Related]
4. Determination of in vitro hepatotoxic potencies of a series of perfluoroalkyl substances (PFASs) based on gene expression changes in HepaRG liver cells.
Louisse J; Fragki S; Rijkers D; Janssen A; van Dijk B; Leenders L; Staats M; Bokkers B; Zeilmaker M; Piersma A; Luijten M; Hoogenboom R; Peijnenburg A
Arch Toxicol; 2023 Apr; 97(4):1113-1131. PubMed ID: 36864359
[TBL] [Abstract][Full Text] [Related]
5. The impact of legacy and novel perfluoroalkyl substances on human cytochrome P450: An in vitro study on the inhibitory potential and underlying mechanisms.
Amstutz VH; Cengo A; Sijm DTHM; Vrolijk MF
Toxicology; 2022 Feb; 468():153116. PubMed ID: 35121066
[TBL] [Abstract][Full Text] [Related]
6. Developing potency factors for thyroid hormone disruption by PFASs using TTR-TRβ CALUX® bioassay and assessment of PFASs mixtures in technical products.
Behnisch PA; Besselink H; Weber R; Willand W; Huang J; Brouwer A
Environ Int; 2021 Dec; 157():106791. PubMed ID: 34364217
[TBL] [Abstract][Full Text] [Related]
7. Mixtures of per- and poly-fluoroalkyl substances (PFAS) reduce the in vitro activation of human T cells and basophils.
Maddalon A; Pierzchalski A; Kretschmer T; Bauer M; Zenclussen AC; Marinovich M; Corsini E; Herberth G
Chemosphere; 2023 Sep; 336():139204. PubMed ID: 37315852
[TBL] [Abstract][Full Text] [Related]
8. Benchmark dose calculations for PFAS exposure based on two data sets on immunotoxic effects.
Budtz-Jørgensen E; Grandjean P
Environ Health; 2023 May; 22(1):40. PubMed ID: 37147704
[TBL] [Abstract][Full Text] [Related]
9. Consideration of pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS).
Ehrlich V; Bil W; Vandebriel R; Granum B; Luijten M; Lindeman B; Grandjean P; Kaiser AM; Hauzenberger I; Hartmann C; Gundacker C; Uhl M
Environ Health; 2023 Feb; 22(1):19. PubMed ID: 36814257
[TBL] [Abstract][Full Text] [Related]
10. Internal relative potency factors based on immunotoxicity for the risk assessment of mixtures of per- and polyfluoroalkyl substances (PFAS) in human biomonitoring.
Bil W; Ehrlich V; Chen G; Vandebriel R; Zeilmaker M; Luijten M; Uhl M; Marx-Stoelting P; Halldorsson TI; Bokkers B
Environ Int; 2023 Jan; 171():107727. PubMed ID: 36628859
[TBL] [Abstract][Full Text] [Related]
11. UniProt: the Universal Protein Knowledgebase in 2023.
UniProt Consortium
Nucleic Acids Res; 2023 Jan; 51(D1):D523-D531. PubMed ID: 36408920
[TBL] [Abstract][Full Text] [Related]
12. PFAS levels and determinants of variability in exposure in European teenagers - Results from the HBM4EU aligned studies (2014-2021).
Richterová D; Govarts E; Fábelová L; Rausová K; Rodriguez Martin L; Gilles L; Remy S; Colles A; Rambaud L; Riou M; Gabriel C; Sarigiannis D; Pedraza-Diaz S; Ramos JJ; Kosjek T; Snoj Tratnik J; Lignell S; Gyllenhammar I; Thomsen C; Haug LS; Kolossa-Gehring M; Vogel N; Franken C; Vanlarebeke N; Bruckers L; Stewart L; Sepai O; Schoeters G; Uhl M; Castaño A; Esteban López M; Göen T; Palkovičová Murínová Ľ
Int J Hyg Environ Health; 2023 Jan; 247():114057. PubMed ID: 36327670
[TBL] [Abstract][Full Text] [Related]
13. Perfluoroalkyl substances (PFASs) decrease the expression of recombination-activating genes (RAG1 and RAG2) in human B lymphoma Namalwa cells.
Janssen AWF; Louisse J; Rijkers D; Pinckaers NET; Hoekstra SA; Hoogenboom RLAP; Peijnenburg AACM; Beekmann K
Arch Toxicol; 2022 Nov; 97(2):457-68. PubMed ID: 36326898
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
